SunOpta Shareholders Approve Refresco Acquisition, Clearing Critical Vote Hurdle

What happened

SunOpta's shareholders voted on April 16, 2026 to approve the proposed all-cash acquisition by Refresco for $6.50 per share, as announced on April 17, 2026. This approval meets the key condition requiring ≥66⅔% of votes cast, a milestone highlighted in the DeepValue report as essential for the deal's progression. The transaction's completion now depends on an Ontario court Final Order expected around April 22, 2026, and antitrust clearances in the U.S., Canada, and Vietnam, with a strict cap that dissent rights not exceed 5% of shares. With shareholder consent secured, the investment thesis shifts focus to regulatory reviews and court approvals, which could still delay or terminate the deal if issues arise. This event aligns with the base case scenario but does not eliminate the material downside risks associated with the leveraged standalone business if the deal fails.

Implication

The shareholder approval increases the probability of deal closure, but with the stock trading at the $6.50 offer price, upside is capped, leaving investors vulnerable to regulatory delays or failure. If antitrust reviews expand via Second Requests or if dissent exceeds 5%, the deal could break, repricing the stock to around $4.50 based on the bear scenario. Investors should closely watch for the court order by April 22 and any regulatory disclosures by June 30 to assess timing risks and potential slippage. Given SunOpta's leveraged balance sheet with net debt of $372 million and margin volatility from unhedged input costs, a deal delay would significantly impair equity value. Therefore, while this milestone is positive, the investment remains asymmetric with downside risk unless shares trade below the attractive entry point of $6.25.

Thesis delta

The thesis shifts as shareholder approval is now confirmed, reducing one execution risk and supporting the base case of a Q2 2026 close. However, the core thesis remains unchanged: at $6.50, the stock is fully valued for the deal, and the remaining regulatory and dissent risks maintain a negative asymmetry. Investors should now focus on the court order and antitrust milestones, which could still alter the timeline or outcome.